MYCOLab Ai Logo - gold and army green

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

Summary

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Background

Invasive fungal infections present a significant clinical challenge with limited broad-spectrum treatment options. SCY-247 is a novel second-generation triterpenoid antifungal with broad-spectrum activity against yeasts, molds, and dimorphic fungi, including azole- and echinocandin-resistant strains, and can be administered both orally and intravenously.

Objective

To evaluate the in vivo efficacy of SCY-247 in murine models of invasive fungal infections caused by Candida species and Rhizopus delemar, assessing dose-dependent responses based on fungal burden and survival outcomes.

Results

SCY-247 demonstrated potent dose-dependent activity in all three models. Significant reductions in kidney fungal burden were observed against C. albicans at doses ≥10 mg/kg and against C. glabrata at doses ≥16 mg/kg. Against pulmonary mucormycosis, doses ≥32 mg/kg resulted in prolonged survival and reduced lung and brain fungal burden.

Conclusion

SCY-247 demonstrated significant in vivo antifungal activity in murine models of invasive candidiasis and pulmonary mucormycosis with dose- and exposure-dependent responses, supporting its potential as a broad-spectrum antifungal therapeutic option.
  • Published in:Open Forum Infectious Diseases,
  • Study Type:Preclinical Study,
  • Source: 10.1093/ofid/ofae631.031, PMC11778151
Scroll to Top